EMA Withdrawn: Krystexxa (pegloticase) — Crealta Pharmaceuticals Ireland Limited

View source ↗

Summary

EMA withdrew Krystexxa (pegloticase) from the market for gout.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• KRYSTEXXA (pegloticase)

Snippet

Status: Withdrawn. Therapeutic area: Gout. MAH: Crealta Pharmaceuticals Ireland Limited. Decision date: 30/06/2016